Puma said 2,841 patients diagnosed with early stage breast cancer who had undergone surgery were part of its Phase 3 clinical trials of Neratinib.

The Los Angeles-based company plans to file for regulatory approval for Neratinib in 2015. The medication could also be used to treat non-small cell lung cancer and tumors. The company also announced an amended licensing deal with Pfizer that makes Pump responsible for expenses tied to clinical trials.

Puma, which closed at $59 during normal trading hours, ran up sharply from November to Feb. 21, when previously peaked at about $130 before a broad-based biotech sell off pummeled the stock to $53.